United States
Print page content Print
Increase text size Decrease text size
Text Size

VANGUARD® Plus CPV

Aids in protecting dogs against canine parvoviral enteritis caused by canine parvovirus (CPV) including cross-protection against CPV-2c

VANGUARD PLUS CPV

VANGUARD Plus CPV is licensed for vaccination of healthy dogs 6 weeks of age or older as an aid in the prevention of canine parvoviral enteritis caused by canine parvovirus (CPV).  In addition, cross-protection against CPV type 2c has been demonstrated.

VANGUARD Plus CPV is a high-titer, modified-live canine parvovirus (CPV) strain attenuated by low passage on an established canine cell line. The combination of high titer and low passage gives VANGUARD Plus CPV the immunogenic properties capable of stimulating active immunity in the presence of maternal antibodies. Some puppies may have higher levels of maternal antibodies than those evaluated in our pivotal efficacy study.

Expand All
    • Inherently greater immunogenicity of a low-passage CPV produced at high titer can help stimulate active immunity in the presence of maternal antibodies. Serum neutralization titers as low as 1:4 have been shown to prevent active immunization by conventional vaccines. VANGUARD Plus CPV has been shown to successfully immunize dogs with pre-vaccination serum neutralization (SN) titers, some as high as 1:64.
    • Customer-friendly packaging includes peel-off labels to make record-keeping faster and more accurate, a color-coded organizing system, and an easy-open safety band.
    • VANGUARD Plus CPV is supported by our Companion Animal Immunization Support Guarantee (ISG).
  • DIRECTIONS:

    1. General Directions: Vaccination of healthy dogs is recommended. Shake well. Aseptically administer 1 mL subcutaneously or intramuscularly.

    2. Primary Vaccination: Healthy dogs 6 weeks of age or older should receive 3 doses, each administered 3 weeks apart.

    3. Revaccination: Annual revaccination with a single dose is recommended, although, as recommended by the American Veterinary Medical Association and its Council on Biologic and Therapeutic Agents, the attending veterinarian should determine the frequency of revaccination based on the animal's lifestyle and risk of exposure.*


    *American Veterinary Medical Association, Position Statements on Biologics, June 2001.


     


PRECAUTIONS:

1. Store at 2°-7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.

2. Use entire contents when first opened.

3. Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.

4. Burn containers and all unused contents.

5. Contains gentamicin and amphotericin B as preservatives.

6. Vaccination of pregnant bitches should be avoided.

7. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

8. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

Technical inquiries should be directed to Zoetis Veterinary Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).

For veterinary use only